DỮ LIỆU BÁO CÁO THƯỜNG NIÊN
CÁC CÔNG TY NIÊM YẾT NƯỚC NGOÀI

Báo cáo thường niên năm 2019 của IBIO, Inc.

iBio is developing proprietary products for the treatment of a range of fibrotic diseases including idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. IBIO-CFB03, produced using the Company's proprietary gene expression technology, is the first product candidate from this program being advanced for IND development. The Company also offers proprietary products and product licenses to others based on its proprietary technologies, providing collaborators full support for turn-key implementation of its technology for protein therapeutics and vaccines.

TÊN CÔNG TY / COMPANY
IBIO, Inc.

SÀN CHỨNG KHOÁN / STOCK EXCHANGE
NYSE (US)

MÃ CHỨNG KHOÁN / TICKER
IBIO

KỲ BÁO CÁO
2019

NGÀNH / INDUSTRY
Biotechnology

LĨNH VỰC / SECTOR
Healthcare